LA JOLLA, Calif. — You could easily mistake it for a big CD rack. Inside the lab at the California Institute of Biomedical Research, known as Calibr, sits a stacked array of several dozen plastic ...

In March 2012, the California Institute for Biomedical Research (Calibr), a nonprofit devoted to translating basic science into drug candidates, launched amid much fanfare. Fueling the hype was an ...

AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed ...

LA JOLLA, CA— Calibr, a division of Scripps Research focused on the “bench to bedside” development of transformative medicines, today announced encouraging preliminary data from the first nine ...

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the ...

LA JOLLA, Calif., May 23, 2014 /PRNewswire-USNewswire/ -- The California Institute for Biomedical Research (Calibr) has received a Translation Award from the Wellcome Trust to develop a novel ...

Peter G. Schultz, the noted chemist and biotech entrepreneur, sure doesn’t think small. His new biomedical research institute in La Jolla, called Calibr, is researching CAR T cell therapy for cancer, ...

Drug manufacturer AbbVie, and a nonprofit drug discovery division of Scripps Research, Calibr, announced earlier this week that they are partnering to develop chimeric antigen receptor (CAR-T) cell ...

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the ...

A promising — yet dangerous — form of cancer treatment might soon be less risky and more effective thanks to new research from San Diego’s cancer group at Calibr. The researchers, now under the ...